PE20170304A1 - Composiciones antimicrobianas con agentes efervescentes - Google Patents
Composiciones antimicrobianas con agentes efervescentesInfo
- Publication number
- PE20170304A1 PE20170304A1 PE2016002748A PE2016002748A PE20170304A1 PE 20170304 A1 PE20170304 A1 PE 20170304A1 PE 2016002748 A PE2016002748 A PE 2016002748A PE 2016002748 A PE2016002748 A PE 2016002748A PE 20170304 A1 PE20170304 A1 PE 20170304A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- antimicrobial compositions
- effervescent agents
- composition
- quinolinecarboxylate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000000845 anti-microbial effect Effects 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 2
- XOQQVKDBGLYPGH-UHFFFAOYSA-N 2-oxo-1h-quinoline-3-carboxylic acid Chemical class C1=CC=C2NC(=O)C(C(=O)O)=CC2=C1 XOQQVKDBGLYPGH-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 229960002920 sorbitol Drugs 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Se refiere a una composicion farmaceutica que comprende: a) un derivado de acido quinolona carboxilico de formula I, donde R1 es H o un grupo protector carboxilo; R2 es hidroxilo, entre otros; R3 y R4 son H o halogeno; R5 es halogeno o un grupo amino ciclico saturado opcionalmente sustituido; R6 es H, halogeno, entre otros; X, Y y Z son, independientemente, N, -CH= o -CR7=; con la condicion de que al menos uno de X, Y y Z es N; y W es N o -CR8=; donde un compuesto seleccionado es D-glucitol, 1-desoxi-1-(metilamino), 1-(6- amino-3,5-difluoro- 2-piridinil)-8-cloro-6- fluor-1,4-dihidro-7- (3 -hidroxi-1-azetidinil)-4-oxo-3-quinolincarboxilato y b) un agente efervescente. Dicha composicion tiene tolerabilidad gastrointestinal mejorada y/o menos probabilidad de causar efectos secundarios; siendo util para el tatamiendo de infecciones microbianas
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014786P | 2014-06-20 | 2014-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170304A1 true PE20170304A1 (es) | 2017-04-19 |
Family
ID=54868661
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016002748A PE20170304A1 (es) | 2014-06-20 | 2015-06-19 | Composiciones antimicrobianas con agentes efervescentes |
| PE2021000031A PE20210927A1 (es) | 2014-06-20 | 2015-06-19 | Composiciones antimicrobianas con agentes efervescentes |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000031A PE20210927A1 (es) | 2014-06-20 | 2015-06-19 | Composiciones antimicrobianas con agentes efervescentes |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20150366857A1 (es) |
| EP (3) | EP3157510B1 (es) |
| JP (2) | JP6995479B2 (es) |
| CN (2) | CN106572982B9 (es) |
| AR (1) | AR100920A1 (es) |
| AU (3) | AU2015276954B2 (es) |
| BR (1) | BR112016029761B1 (es) |
| CA (1) | CA2952950C (es) |
| CL (2) | CL2016003273A1 (es) |
| CR (2) | CR20160592A (es) |
| CY (2) | CY1121995T1 (es) |
| DK (2) | DK3157510T3 (es) |
| EA (1) | EA034152B1 (es) |
| EC (1) | ECSP16095540A (es) |
| ES (2) | ES2732865T3 (es) |
| HR (2) | HRP20191133T1 (es) |
| HU (2) | HUE056298T2 (es) |
| IL (1) | IL249622A0 (es) |
| LT (2) | LT3581180T (es) |
| MX (2) | MX386171B (es) |
| PE (2) | PE20170304A1 (es) |
| PH (2) | PH12022550979A1 (es) |
| PL (2) | PL3581180T3 (es) |
| PT (2) | PT3581180T (es) |
| RS (2) | RS62538B1 (es) |
| SI (2) | SI3157510T1 (es) |
| SM (2) | SMT202100618T1 (es) |
| SV (1) | SV2016005349A (es) |
| TR (1) | TR201909417T4 (es) |
| TW (2) | TWI732337B (es) |
| UY (1) | UY36184A (es) |
| WO (1) | WO2015196027A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022240897A1 (en) * | 2021-05-10 | 2022-11-17 | Sepelo Therapeutics, Llc | Pharmaceutical composition comprising delafloxacin for administration into the lung |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194617A (en) * | 1988-12-17 | 1993-03-16 | Meiji Seika Kaisha, Ltd. | 2,3-disubstituted-4-hydroxyquinoline derivatives |
| US5223264A (en) * | 1989-10-02 | 1993-06-29 | Cima Labs, Inc. | Pediatric effervescent dosage form |
| GB9402203D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
| DE69628466T2 (de) | 1995-09-22 | 2004-04-01 | Wakunaga Pharmaceutical Co., Ltd. | Zwischenverbindungen zur Herstellung von neunen Pyridoncarbonsäurederivate oder deren Salzen |
| US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
| DE19814256A1 (de) * | 1998-03-31 | 1999-10-07 | Asta Medica Ag | Feste, schnellzerfallende Cetirizin-Formulierungen |
| IL141977A0 (en) | 1998-09-14 | 2002-03-10 | Ranbaxy Lab Ltd | Orally administered controlled drug delivery system providing temporal and spatial control |
| US6187317B1 (en) * | 1999-07-14 | 2001-02-13 | Judith Taylor | Natural anti-diarrheal composition and method |
| US6414036B1 (en) * | 1999-09-01 | 2002-07-02 | Van Beek Global/Ninkov Llc | Composition for treatment of infections of humans and animals |
| JP2005097116A (ja) | 1999-11-11 | 2005-04-14 | Wakunaga Pharmaceut Co Ltd | キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法 |
| WO2003101431A1 (en) * | 2002-06-04 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
| EP2816033A1 (en) | 2004-07-30 | 2014-12-24 | Abbvie Inc. | Preparation of pyridonecarboxylic acid antibacterials |
| MX2007004111A (es) * | 2004-10-08 | 2007-06-14 | Abbott Lab | Sal y formas cristalinas de la misma de un farmaco. |
| EP2486942B1 (en) * | 2004-11-24 | 2018-10-10 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| HRP20120502T1 (hr) | 2005-04-11 | 2012-07-31 | Abbott@Laboratories | Farmaceutske smjese s poboljšanim profilom otapanja za slabo topljive lijekove |
| DE602005007205D1 (de) | 2005-07-19 | 2008-07-10 | Ethypharm Sa | Gastroretentive Zusammensetzungen und Verfahren zur Herstellung |
| US7611739B2 (en) | 2006-01-06 | 2009-11-03 | Amerilab Technologies, Inc. | Method of using guava extract and composition including guava extract |
| US20080171158A1 (en) * | 2006-08-11 | 2008-07-17 | Aqua Resources Corporation | Nanoplatelet copper hydroxides and methods of preparing same |
| CN1943561A (zh) * | 2006-08-23 | 2007-04-11 | 北京阜康仁生物制药科技有限公司 | 普卢利沙星口腔崩解片及其制备方法 |
| PL2124884T3 (pl) | 2006-12-22 | 2020-01-31 | Ironwood Pharmaceuticals, Inc. | Metody i kompozycje do leczenia zaburzeń przełyku |
| NZ580972A (en) * | 2007-06-04 | 2012-02-24 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
| JP6063123B2 (ja) * | 2008-11-15 | 2017-01-18 | メリンタ セラピューティクス、インク | 抗菌性組成物 |
| WO2010096551A2 (en) * | 2009-02-18 | 2010-08-26 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compositions |
| GB201020076D0 (en) * | 2010-11-26 | 2011-01-12 | Liverpool School Tropical Medicine | Antimalarial compounds |
| AR084824A1 (es) * | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| ES2705923T3 (es) * | 2011-01-14 | 2019-03-27 | Spero Trinem Inc | Formas sólidas de inhibidor de girasa (R)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1H-bencimidazol-2-il]urea |
| JP2013034468A (ja) * | 2011-08-10 | 2013-02-21 | Nisshin Sugar Mfg Co Ltd | 発泡成型甘味料 |
| US20140328884A1 (en) * | 2011-12-16 | 2014-11-06 | Celanese Eva Performance Polymers, Inc. | Controlled release vehicles having desired void volume architectures |
| CN102697751A (zh) * | 2012-05-30 | 2012-10-03 | 河南牧翔动物药业有限公司 | 一种畜禽专用恩诺沙星泡腾分散片及其制备方法 |
-
2015
- 2015-06-18 TW TW108140999A patent/TWI732337B/zh active
- 2015-06-18 TW TW104119676A patent/TWI705814B/zh active
- 2015-06-19 CA CA2952950A patent/CA2952950C/en active Active
- 2015-06-19 DK DK15810507.2T patent/DK3157510T3/da active
- 2015-06-19 WO PCT/US2015/036605 patent/WO2015196027A1/en not_active Ceased
- 2015-06-19 CN CN201580044451.8A patent/CN106572982B9/zh active Active
- 2015-06-19 ES ES15810507T patent/ES2732865T3/es active Active
- 2015-06-19 LT LTEP19165084.5T patent/LT3581180T/lt unknown
- 2015-06-19 HU HUE19165084A patent/HUE056298T2/hu unknown
- 2015-06-19 SM SM20210618T patent/SMT202100618T1/it unknown
- 2015-06-19 CR CR20160592A patent/CR20160592A/es unknown
- 2015-06-19 CN CN202210565182.1A patent/CN114831955B/zh active Active
- 2015-06-19 PH PH1/2022/550979A patent/PH12022550979A1/en unknown
- 2015-06-19 RS RS20211307A patent/RS62538B1/sr unknown
- 2015-06-19 EA EA201692532A patent/EA034152B1/ru unknown
- 2015-06-19 SM SM20190348T patent/SMT201900348T1/it unknown
- 2015-06-19 ES ES19165084T patent/ES2897576T3/es active Active
- 2015-06-19 RS RS20190773A patent/RS59064B1/sr unknown
- 2015-06-19 SI SI201530783T patent/SI3157510T1/sl unknown
- 2015-06-19 LT LTEP15810507.2T patent/LT3157510T/lt unknown
- 2015-06-19 US US14/744,432 patent/US20150366857A1/en not_active Abandoned
- 2015-06-19 BR BR112016029761-0A patent/BR112016029761B1/pt active IP Right Grant
- 2015-06-19 SI SI201531733T patent/SI3581180T1/sl unknown
- 2015-06-19 CR CR20200565A patent/CR20200565A/es unknown
- 2015-06-19 EP EP15810507.2A patent/EP3157510B1/en active Active
- 2015-06-19 HU HUE15810507 patent/HUE044764T2/hu unknown
- 2015-06-19 JP JP2016574040A patent/JP6995479B2/ja active Active
- 2015-06-19 HR HRP20191133TT patent/HRP20191133T1/hr unknown
- 2015-06-19 PE PE2016002748A patent/PE20170304A1/es unknown
- 2015-06-19 DK DK19165084.5T patent/DK3581180T3/da active
- 2015-06-19 TR TR2019/09417T patent/TR201909417T4/tr unknown
- 2015-06-19 AR ARP150101976A patent/AR100920A1/es unknown
- 2015-06-19 EP EP19165084.5A patent/EP3581180B1/en active Active
- 2015-06-19 EP EP21188004.2A patent/EP3919057A1/en active Pending
- 2015-06-19 PT PT191650845T patent/PT3581180T/pt unknown
- 2015-06-19 PT PT15810507T patent/PT3157510T/pt unknown
- 2015-06-19 PL PL19165084T patent/PL3581180T3/pl unknown
- 2015-06-19 PH PH1/2016/502548A patent/PH12016502548B1/en unknown
- 2015-06-19 PE PE2021000031A patent/PE20210927A1/es unknown
- 2015-06-19 AU AU2015276954A patent/AU2015276954B2/en active Active
- 2015-06-19 MX MX2019012608A patent/MX386171B/es unknown
- 2015-06-19 MX MX2016017350A patent/MX368940B/es active IP Right Grant
- 2015-06-19 PL PL15810507T patent/PL3157510T3/pl unknown
- 2015-06-19 HR HRP20211685TT patent/HRP20211685T1/hr unknown
- 2015-06-22 UY UY0001036184A patent/UY36184A/es not_active Application Discontinuation
-
2016
- 2016-12-18 IL IL249622A patent/IL249622A0/en unknown
- 2016-12-20 SV SV2016005349A patent/SV2016005349A/es unknown
- 2016-12-20 CL CL2016003273A patent/CL2016003273A1/es unknown
- 2016-12-20 EC ECIEPI201695540A patent/ECSP16095540A/es unknown
-
2019
- 2019-06-26 CY CY20191100664T patent/CY1121995T1/el unknown
-
2020
- 2020-01-28 US US16/774,709 patent/US20200237744A1/en not_active Abandoned
- 2020-07-15 JP JP2020121083A patent/JP7149991B2/ja active Active
- 2020-10-17 AU AU2020256457A patent/AU2020256457B2/en active Active
- 2020-12-03 CL CL2020003153A patent/CL2020003153A1/es unknown
-
2021
- 2021-11-04 CY CY20211100955T patent/CY1125395T1/el unknown
- 2021-12-14 AU AU2021286284A patent/AU2021286284B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004776A2 (es) | Nuevos derivados de quinolina-3-carboxamida antihelmínticos | |
| DOP2020000023A (es) | Nuevos derivados de quinolina | |
| MX373678B (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| EA201690979A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
| EA201492011A1 (ru) | Безводные фармацевтические составы для местного применения | |
| MX2021000189A (es) | Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias. | |
| MX2017012545A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| EA201690859A1 (ru) | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli | |
| JOP20200004A1 (ar) | تركيبات طويلة المفعول | |
| BR112016024235A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| BR112018074985A2 (pt) | composições antibacterianas | |
| MX2019011908A (es) | Macrociclos de peptidos anti-bacterianos y uso de los mismos. | |
| MX2017012535A (es) | Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| MX2017015812A (es) | Formulaciones farmaceuticas inyectables de lefamulina. | |
| MX2017014080A (es) | Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas. | |
| EA202090750A1 (ru) | Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| MX2015010790A (es) | Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc. | |
| PE20170304A1 (es) | Composiciones antimicrobianas con agentes efervescentes | |
| BR112016012053A2 (pt) | Composições antibacterianas | |
| BR112016024236A2 (pt) | composições farmacêuticas compreendendo agentes antibacterianos | |
| EA201692531A1 (ru) | Способы лечения инфекций | |
| UA113722C2 (uk) | Фармацевтична композиція |